Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165563 | 0.89 | GFER (0.50) | MAOBGFERCYP19A1MAOATDP1 | |
| SCHEMBL13625390 | 0.88 | GFER (0.54) | MAOBGFERCYP19A1MAOATDP1 | |
| SCHEMBL31553484 | 0.88 | GFER (0.59) | MAOBGFERCYP19A1MAOAKCNH2 | |
| SCHEMBL9519264 | 0.87 | GFER (0.45) | MAOBGFERCYP19A1MAOAKCNH2 | |
| SCHEMBL11207570 | 0.82 | MAOB (0.57) | MAOBGFERCYP19A1MAOATDP1 | |
| SCHEMBL18195304 | 0.82 | L3MBTL1 (0.49) | MAOBKCNH2TDP1L3MBTL1IDO1 | |
| SCHEMBL17230493 | 0.81 | TDP1 (0.55) | MAOBTDP1L3MBTL1IDO1TAAR1 | |
| SCHEMBL11404682 | 0.81 | MAOB (0.50) | MAOBGFERCYP19A1MAOAKCNH2 | |
| SCHEMBL10378466 | 0.81 | IDO1 (0.53) | TDP1L3MBTL1IDO1 | |
| SCHEMBL28984108 | 0.81 | HRH3 (0.44) | MAOBGFERCYP19A1MAOAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288566-B2 | N-hydroxyformamidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060004078-A1 | N-hydroxyformamidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004078-A1 | N-hydroxyformamidine derivatives | FLT4, FLT1, PGF | MAOB 276/4885GFER 1110/4885CYP19A1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.